Efficacy and Safety of LBSA0103 Versus Hyruan Plus Injection in Patients With Knee Osteoarthritis
An Double-blind, Active-controlled, Parallel-group, Randomized, Multi-center Study to Compare Efficacy and Safety of LBSA0103 Once Versus Hyruan Plus Injection Once Weekly for 3weeks in the Treatment of Patients With Osteoarthritis of the Knee
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Seoul
-
Jongno-gu, Seoul, Korea, Republic of
- Seoul National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Over 40 years of age
- Kellgren & Lawrence grade I-III
- If there is more than one knee having a weight bearing pain of at least 40mm evaluated by 100mm VAS
- Be willing to discontinue all nonsteroidal anti-inflammatory drugs(NSAIDs), analgesics, condroichin sulfate/glucosamine or physical therapy for the duration of the study
Exclusion Criteria:
- Body mass index > 32
- Have rheumarthritis
- Patients who have a weight-bearing pain of less than 40mm on both knees when measured by 100mm-VAS
- Have Sudek's atrophy, Paget's disease, Spinal disc herniation
- Kellgren & Lawrence Grade IV
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Placebo and then LBSA0103
The experimental group receive once weekly for 2 weeks intraarticular injections of Placebo(saline).
And then, they receive once intraarticular injections of LBSA0103 into the target knee.
|
First 2 weeks Placebo(2ml) once weekly in experimental group
at third week LBSA0103(60mg) once in experimental group
|
|
Active Comparator: Hyruan Plus
The control group received once weekly for 3 weeks intraarticular injections of Hyruan Plus Inj.
into the target knee.
|
Hyruan Plus Inj.
(2ml)once weekly for 3 weeks in control group
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Weight-bearing pain
Time Frame: 12 weeks after the last injection
|
using 100mm-VAS
|
12 weeks after the last injection
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Weight-bearing pain
Time Frame: 1,6 weeks after the last injection
|
using 100mm-VAS
|
1,6 weeks after the last injection
|
|
WOMAC-likert assessment
Time Frame: 1,6,12 weeks after the last injection
|
Pain, Function, Stiffness, Total score
|
1,6,12 weeks after the last injection
|
|
Patient Global Assessment
Time Frame: 1,6,12 weeks after the last injection
|
using 100mm-VAS
|
1,6,12 weeks after the last injection
|
|
Investigator Global Assessment
Time Frame: 1,6,12 weeks after the last injection
|
using 100mm-VAS
|
1,6,12 weeks after the last injection
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- LG-HACL010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.